Lantheus' pipeline-building drive in radiopharma ... which was extended last year with the acquisition of NTI-1309, a PET oncology imaging agent that targets cancer biomarker fibroblast activation ...

"We are excited to be partnering with Lantheus to bring Granzyme B PET imaging to the forefront. This strategic collaboration creates a clear path to commercialization with an ideal partner in the ...

Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, ...